At the news
? BULLISHIMPACT 6/10 6-K filed Jun 23, 2026 at 16:01 ET
Alpha Tau announced the first-ever treatment of a recurrent glioblastoma patient outside the U.S. using its Alpha DaRT technology at Hadassah University Medical Center in Israel. The procedure was completed safely without unexpected complications, marking the first international clinical application of the brain-specific delivery system and adding momentum to the ongoing U.S. REGAIN trial.
- First recurrent glioblastoma patient treated with Alpha DaRT outside the U.S., and first in Israel, at Hadassah University Medical Center.
- Procedure used proprietary brain applicator with real-time stereotactic neuro-navigation via a single minimally-invasive burr hole.
- Patient was a 77-year-old male with recurrent glioblastoma following surgery and radiation therapy; procedure completed safely without unexpected complications.
- Treatment was under the ALL clinical protocol, a broad-access study at Hadassah open to patients with solid tumors amenable to Alpha DaRT.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access